Treating paediatric community-acquired pneumonia in the era of antimicrobial resistance

Acta Paediatr. 2013 Dec;102(465):25-33. doi: 10.1111/apa.12503.

Abstract

Increasing levels of paediatric community-acquired pneumonia (CAP), caused by drug-resistant bacteria and antimicrobial resistance, vary with age and countries and, in some cases, serotypes. When empirical first-line treatment administration fails, paediatricians should consider second-line treatments based on the prevalence of local resistance. A more judicious use of antimicrobial agents is also required.

Conclusion: Knowledge of local epidemiology and an appropriate use of antimicrobial drugs are necessary to treat CAP in this era of antimicrobial resistance.

Keywords: Antimicrobial resistance; Children; Community-acquired pneumonia; Drug-resistant bacteria; Paediatricians.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / therapeutic use*
  • Child
  • Community-Acquired Infections / drug therapy
  • Community-Acquired Infections / microbiology
  • Drug Resistance, Bacterial*
  • Humans
  • Methicillin-Resistant Staphylococcus aureus
  • Microbial Sensitivity Tests
  • Mycoplasma pneumoniae
  • Pneumonia, Bacterial / drug therapy*
  • Pneumonia, Bacterial / microbiology
  • Streptococcus pneumoniae

Substances

  • Anti-Bacterial Agents